Project Grant HT94252510766
Award Date 9/1/25
Completion Date 8/31/28
Dollars Obligated $1.1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pittsburgh, PA 15260, USA
Similar Awards
- This Project Grant award, titled "OVERCOMING IMMUNOTHERAPY RESISTANCE IN ACRAL MELANOMA", is provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The $1,183,560 award to the University of Pittsburgh will support advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The research project, running from September 1, 2025 to August 31, 2028, will focus on...
- The University of Pittsburgh has been awarded a $726,989 Project Grant from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) to conduct research on "IMMUNOTHERAPEUTIC TARGETING OF SLC39A9 IN CDKN2A-LOW MELANOMA." The three-year award, commencing on September 15, 2025, aims to advance biomedical research to transform healthcare for military service members, veterans, and the broader public. The research project will investigate medical...
- The University of Pittsburgh has been awarded a $681,379 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to evaluate B-T cell cross talk within tertiary lymphoid structures in melanoma progression and immune checkpoint blockade. The award has a performance period from July 1, 2024 to June 30, 2027. This research project aims to enhance understanding of the immune processes involved in melanoma development and response to...
- This Project Grant award, worth $647,861.00, was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of Pittsburgh. The funding will support a 3-year research project evaluating the interplay between B-cells and T-cells within the tumor microenvironment of melanoma, and the impact on immune checkpoint blockade therapies. The University of Pittsburgh, a major recipient of federal biomedical research grants, will...
- The University of Pittsburgh was awarded a $954,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will support research from May 2023 to May 2026 aimed at epigenetic reprogramming to target senescent ovarian cancer cells and overcome therapeutic resistance. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public...
- The University of Pittsburgh was awarded a $925,680 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from August 1, 2023 to July 31, 2027 targeting the IGFBP2-SRC signaling axis to block metastatic spread and tumor-mesothelial crosstalk. Through this research, the University aims to develop medical solutions for the battlefield by investigating approaches to prevent cancer metastasis. The Military...
- The University of Pittsburgh was awarded a $795,001 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program. The three-year award will fund a research project from September 2022 to August 2025 to interrogate the impact of B cells and tertiary lymphoid structures in melanoma brain metastases. Through this funding, the University of Pittsburgh will investigate medical solutions for the battlefield by supporting applied and advanced...
- The University of Pittsburgh has been awarded a $602,986 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award, effective August 1, 2024 through August 31, 2026, will fund a research project titled "A T CELL-GUIDED APPROACH TO DEVELOP ANTIGEN-SPECIFIC IMMUNOTHERAPIES FOR PEDIATRIC BRAIN TUMORS." This project aims to develop innovative immunotherapies for treating pediatric brain tumors by leveraging the...
- The University of Pittsburgh received a $454,142.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "FERROPTOSIS AS A METABOLIC VULNERABILITY OF CYCLIN E-HIGH OVARIAN CANCER". This 2-year research project, with a performance period from May 2024 to May 2026, aims to investigate metabolic vulnerabilities in a specific type of ovarian cancer. The University of Pittsburgh is the primary...
- This $1,264,474 federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports the University of Pittsburgh's research on "Molecular Insights into Immune Suppression in Kidney Cancer and Novel Therapeutic Opportunities". The grant, effective September 1, 2024 through August 31, 2028, will fund the university's investigations into improving understanding of immune system mechanisms involved in kidney cancer and...